OncoMatch/Clinical Trials/NCT07040956
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Is NCT07040956 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Afatinib for head and neck squamous cell carcinoma.
Treatment: Tislelizumab · Afatinib — This study aimed to compare the efficacy of neoadjuvant low-dose radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone in patients with resectable head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
prior therapy with: anti-PD-1
Cannot have received: anti-PD-L1 therapy
prior therapy with: anti-PD-L1/2
Cannot have received: anti-PD-L2 therapy
prior therapy with: anti-PD-L1/2
Cannot have received: anti-CTLA-4 therapy
prior therapy with: anti-CTLA-4 antibody
Cannot have received: anti-EGFR antibody
prior therapy with: anti-EGFR antibody
Cannot have received: EGFR tyrosine kinase inhibitor
prior therapy with: EGFR-TKIs
Cannot have received: antitumor vaccine
prior therapy with: antitumor vaccine
Cannot have received: active vaccine
any active vaccine against an infectious disease within 4 weeks before the first dose or planned during the study period
Cannot have received: major surgery
major surgery or serious trauma within 4 weeks before the first dose
Cannot have received: investigational drug
Received any investigational drug within 4 weeks prior to the first dose
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 × 10^9/L, hemoglobin ≥ 80 g/L, platelets ≥ 80 × 10^9/L
Kidney function
Creatinine clearance ≥ 60 ml/min
Liver function
ALT, AST and ALP < 2.5× ULN, total bilirubin ≤ 2×ULN; albumin≥ 2.8 g/dL
Cardiac function
INR≤ 1.5, APTT≤ 1.5×ULN; ejection fraction < 50% excluded
Adequate organ and bone marrow function: Absolute neutrophil count ≥ 1.5 × 10^9/L, hemoglobin ≥ 80 g/L, platelets ≥ 80 × 10^9/L; ALT, AST and ALP < 2.5× ULN, total bilirubin ≤ 2×ULN; albumin≥ 2.8 g/dL；Creatinine clearance ≥ 60 ml/min；INR≤ 1.5, APTT≤ 1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07040956 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages